Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease…
seekingalpha.com

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
+54.8% vs SMA 50 · +74.4% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $550.4M $531.6M–$568.4M | — | -$1.17 | — | ±18% | High9 |
FY2026(current) | $3.3B $2.9B–$4.4B | ▲ +494.6% | -$2.52 | — | ±48% | High11 |
FY2027 | $10.0B $8.1B–$11.7B | ▲ +204.6% | -$2.28 | — | ±50% | High11 |
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease…

No company information available